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Over the last decade, surgeons have witnessed dramatic changes in surgical practice as a result of the introduction of new
technological advancement. Some of these changes include refinement of techniques in thyroid cancer surgery. The development
of various endoscopic thyroidectomy techniques, the addition of the da Vinci robot, and the use of operative adjuncts in thyroid
surgery, such as intraoperative neuromonitoring and quick intraoperative parathyroid hormone, havemade thyroid cancer surgery
not only safer and better accepted by patients with thyroid cancer but also offer them more surgical treatment options.
1. Introduction
New technologies have had a positive impact on our ability
to diagnose and treat many surgical conditions [1]. Over
the last decade, surgeons have witnessed dramatic changes
in surgical practice as a result of the introduction of new
technologies or technological advancement. Thyroid cancer
is the commonest endocrine-related tumor. In our locality,
its age-adjusted incidence has doubled over the last 25
years, and a similar trend has been reported elsewhere
[2]. New technologies have had important influence in
the management of this disease. In addition to improving
the preoperative diagnostic accuracy and cancer staging
with various imaging modalities, the techniques of thyroid
cancer surgery have been refined and evolved in this
era of technological advancement. In applying these new
technologies, it is believed that surgical morbidity can be
further reduced, hospital stay shortened, and patient satis-
faction enhanced [3]. The present paper aimed at evaluating
how some of these new technological innovations might
improve patient outcomes and offer new surgical treatment
options for patients diagnosed with thyroid cancer. These
innovations include the development of various endoscopic
thyroidectomy techniques, the addition of the da Vinci robot
surgical system, as well as the use of operative adjuncts
such as intraoperative neuromonitoring (IONM) and quick
intraoperative parathyroid hormone (IOPTH).
2. Endoscopic Thyroidectomy
The application of endoscopic visualization to thyroid
surgery has allowed surgeons to perform thyroidectomy
through incisions far smaller and less visible than the
conventional Kocher’s incision—the so-called “less is more.”
In general, these endoscopic techniques attempt to minimiz-
ing the extent of dissection, improving cosmesis, reducing
postoperative pain, shortening hospital stay, and enhancing
postoperative recovery. Michel Gagner was the first to apply
endoscopic technique to neck surgery when he reported a
totally endoscopic subtotal parathyroidectomy for a 37-year-
old man suffering from familial hyperparathyroidism [4].
Although the endoscopic procedure took over 5 hours, it
demonstrated the technical feasibility and safety. Over the
turn of the last century, an increasing number of different
endoscopic techniques have been described and may be
categorized into namely cervical or direct and extracervical
or indirect approaches [5]. The former is considered as
truly minimally invasive since the skin incisions are small
in the neck with direct access to the thyroid gland. On
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the other hand, the extracervical approach is considered
as an endoscopic instead of minimally invasive approach
because incisions are made distant from the neck and so
the procedure requires more extensive tissue dissections [6].
However, despite its invasiveness, it offers superior early
cosmetic outcome because potentially unsightly scars can be
hidden. This approach has been adopted more often in Asian
countries where cosmesis seems to be of greater concern.
2.1. Cervical/Direct Approaches. These approaches include
the endoscopic lateral cervical approach and the mini-
mally invasive video-assisted thyroidectomy (MIVAT). In
the endoscopic lateral cervical approach, two 2.5mm and
one 10mm trocars are inserted under direct vision along
the anterior border of the sternocleidomastoid muscle on
the side of resection. Using endoscopic instruments, the
dissection starts from the lateral aspect of the thyroid gland
and moves medially with identification of the recurrent
laryngeal nerve (RLN), parathyroid glands and skeleton-
isation of the superior and inferior thyroid vessels [7].
Excellent visualization of RLN and parathyroid glands is
possible with magnification by the endoscope. However,
this technique is limited to unilateral thyroid resection and
its application in thyroid cancer surgery is restricted to
subcentimeter papillary thyroid carcinoma (PTC) detected
by high-resolution ultrasound machines. In contrast, the
MIVAT would be preferred if bilateral thyroid resection is
required because the incision is made in the middle instead
of the lateral aspect of the neck. A 1.5 cm incision is made
in the middle of the neck about 2 cm above the sternal
notch. Blunt dissection is then carried out to separate the
strap muscle from underlying thyroid lobe. A 5mm 30
degree endoscope is placed inside the 1.5 cm wound for
lighting and visualization. The procedure is performed under
endoscopic view with the operating space maintained by
external retraction. This technique was first applied for
selected benign thyroid conditions by Miccoli et al. in 2000
[8]. However, with improvement in techniques, MIVAT has
become increasingly adopted for low-to-intermediate risk
differentiated thyroid cancer [9]. MIVAT has been shown
to achieve similar completeness of resection [10, 11] and 5-
year survival outcomes as those with low and intermediate
risk PTC undergoing conventional thyroidectomy [9]. In
addition, it has been shown that a concomitant central
neck dissection is technically feasible in MIVAT during
initial total thyroidectomy [12]. Also, for patients with low
risk PTC with concomitant lateral lymph node metastases,
a minimally invasive video-assisted functional lateral neck
dissection through a small neck incision is also technically
possible [13].
2.2. Extracervical/Indirect Endoscopic Approaches. Unlike the
cervical approaches, these approaches involve making inci-
sions either in the chest, breast, and/or axilla to hide the
scars with clothing [14]. Ikede et al. first described these
approaches by placing three ports in the axilla with low-
pressure gas insufflation for maintaining the operating space.
Although cosmetic results were excellent, the procedure
was technically demanding and time consuming because of
unintentional easy gas leakage and frequent interference of
the 3 operating surgical instruments in the small available
space in the axilla [15]. Kang et al. modified this technique
by making this approach gasless with the space maintained
by a specially designed skin-lifting external retractor [16].
In this approach, the procedure began with a 4 cm to 5 cm
incision in the axilla and then a subcutaneous space was
created from the axilla to the thyroid gland. To avoid the
problem of interference of instruments, an additional 5mm
port was inserted in the chest area formedial retraction of the
thyroid gland. Kang et al. recently reported their experience
with this approach after performing 581 cases [16]. Among
these patients, 410 patients had low-risk PTC. In their series,
concomitant central neck dissection was performed and the
rate of lymph node metastasis was 27.3% [16].
To further increase the degree of angulations and free-
dom of interference between instruments, a combined axillo-
breast approach was developed utilizing 2 circumareolar
trocars in the breast and a single trocar in the ipsilateral
axilla. This approach was later modified by using bilateral
axillary ports to allow better exposure to both sides of
the thyroid compartment. This approach is now known
as the bilateral axillo-breast approach (BABA). Despite
the extensive tissue dissection, when compared with the
conventional open approach, BABA has been shown to have
similar results in terms of transient hypocalcemia, bleeding,
permanent RLN paralysis and length of hospital stay [17].
More recently, a Korean group tried to eliminate wounds
around the chest or breast areas all together by making
incisions in the axilla and postauricular areas instead. They
reported a small series of 10 patients using this approach
and 7 underwent bilateral thyroid resection for low-risk PTC.
They demonstrated the feasibility of this technique of scarless
(in the neck) thyroid surgery [18].
3. Robotic-Assisted Thyroidectomy
The application and feasibility of the endoscopic approach
was given a further boost with the availability of various
robotic systems such as the da Vinci system (Intuitive
Surgical, Sunnyvale, California). Unlike other cancers such
as prostate cancer, the initial enthusiasm of using the robot
in thyroid cancers was not great because of its relatively
high cost, bulkiness of the robotic arm, and long operating
time. However, since the publication of two large surgical
series demonstrating the feasibility and safety of robotic-
assisted thyroidectomy in differentiated thyroid carcinoma,
an increasing number of specialized surgical centers world-
wide are beginning to accept and perform this procedure.
The theoretical advantages of using the robot over the endo-
scopic approach include the three-dimensional view offer to
the operating surgeon, the flexible robotic instruments with
seven degree of freedom and 90◦ articulation, the increased
tactile sensation, and the ability to filter any hand tremors
[19]. Kang et al. recently reported their experience of 200
robot-assisted total thyroidectomy using the gasless transax-
illary approach for low-risk PTC with concomitant central
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neck dissection and found excellent short-term results in
terms of postoperative pain and patients’ satisfaction [20].
This was followed briefly by another report of 338 benign
and malignant cases using the same transaxillary [21]. To
date, this group has performed over 1000 cases. A separate
Korean group also reported similar results using the da
Vinci robot via the BABA technique [22]. Although both
techniques have been demonstrated to be feasible and safe,
they have been limited to a few high-volume specialized
centers. The surgeons performing these operations have had
years of operating experience with the endoscopic approach
and so the learning curve for a novel, nonendoscopic
thyroid surgeon or someone who predominantly perform
open thyroid procedures, remains undefined but is likely
to be longer than one might think. Furthermore, better
comparative studies such as a randomized controlled trial
between robotic-assisted and endoscopic thyroidectomy are
needed in order to better assess the added patient outcome
benefits over the latter approach.
4. Surgical Adjunct: IONM
RLN injury is a leading cause of litigation in thyroid surgery
[23]. To those with this injury, it not only affects the voice
quality but also diminishes the overall quality of life because
of communication, social and work-related problems [24].
Routine RLN identification is currently the gold standard
of care in thyroid surgery. However, with the availability of
IONM, the issues are whether this new technology could
further enhance RLN preservation and reduce the risk of
iatrogenic RLN injury in thyroid surgery or thyroid cancer
surgery in particular.
Although IONM has been around for over 3 decades,
its widespread usage in the surgical practice only dates
back to 5–10 years. There has been an increased interest
in applying this technique for thyroid surgery because of
the introduction of new and user-friendly devices from
technological advance [25]. Currently, there are two types
of IONM systems, namely, those with electromyographic
(EMG) documentation and those without EMG documenta-
tion. The former involves RLN stimulation with registration
of the elicited laryngeal muscle activity through endoscopic
insertion of electrodes into the vocal fold or with the use
of endotracheal surface electrodes. The latter utilizes RLN
stimulation with observation of posterior cricoarythenoid
muscle contraction or palpation or intraoperative inspection
of vocal cord function [26, 27]. To date, there is no consensus
on which is the best system, and the choice depends on
the availability of which system in your institution and
the operator familiarity or experience. Regardless of which
systems, there are potential flaws and pitfalls. In general, the
positive predictive value (PPV) is proportionally low with
this technology. That means that when a nerve has no signal
during stimulation, it does not mean that it is injured. In
fact, in our experience, the PPV was only 15% in low-risk
thyroid surgery, that is, approximately only 1 out of 9 RLNs
with no signals had an actual injury. This might be due to
some technical errors such as detachment or displacement of
electrodes or poor contact of the probe with the nerve due to
inadequate exposure [28]. Perhaps, direct vagal stimulation
could possibly reduce some of these errors but need more
unnecessary dissection. Even more intriguing is the fact that
this technique is also associated with false negative results,
albeit rarely. In our experience, among 271 nerves at risk,
15 (5.5%) ended with RLN palsy but of these, 7 still had
a positive IONM signals. Therefore, it seems that IONM
might not be able to detect “sublethal” injury to RLN. It is
possible that the action potential could be propagated along
the neural pathway, as detected by the IONM, but not to the
extent of initiating laryngeal muscle contraction during the
postoperative period [25, 28]. Fortunately, all these injuries
would invariably recover.
On the other hand, although the objective of the use
of this device is to avoid RLN injury during thyroid
surgery, the evidence of supporting its routine use has been
weak. The first multicenter study including 29,998 RLNs
at risk confirmed that the incidence of RLN palsy was
not significantly reduced by the additional use of IONM
when routine RLN identification was performed [27]. There
were more than 20 publications addressing this issue but
majority of these studies were heterogeneous in terms of
patients’ characteristics (such as primary operations versus
reoperations or benign versus malignant goiters), IONM
techniques and the extent of resection (i.e., total versus
subtotal lobectomy). A recent literature review could not
definitely draw confirm conclusions or evidence on the
effectiveness of IONM in reducing RLN injury in thyroid
surgery [26]. Furthermore, most studies were either case-
series with no control group or retrospective studies with
inadequate statistical power to demonstrate a difference
between those with or without using IONM. In fact, a
randomized study utilizing approximately 7,000 patients in
each arm of patients undergoing thyroidectomy with or
without IONM will be required to have adequate statistical
power to show a difference in outcome with reference to RLN
paralysis [26, 27]. Interestingly though, the first prospective
randomized study comparing IONM with routine RLN
visualization only was recently published [28]. In this study,
approximately 500 patients were randomized into each
arm. The number of patients recruited in each arm was
based on the principle of detecting a 2% difference in the
incidence of transient RLN injury with a 90% probability at
P < .05. This study did demonstrate a statistically significant
difference in reducing transient RLN injury when IONM
was adopted in comparison with RLN visualization only.
However, as expected, the rate of permanent RLN injury
was similar in the two study arms because of inadequate
statistical power. Nevertheless, despite the inadequate power
of most published IONM studies, there seemed to be a
trend toward improved RLN protection with the use of
this new technology [26]. In addition, the IONM may be
of potential benefit for “difficult” cases such as reoperative
thyroidectomy, locally advanced thyroid cancers or central
neck dissection for cancer recurrence. Perhaps, for the
novel and relatively inexperienced surgeons, the IONM
might prove to be extremely invaluable for these difficult
cases.
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5. Surgical Adjunct: IOPTH or Quick
Intraoperative Parathyroid Assay (qPTH)
as an Assessment of Posthyroidectomy
Hypoparathyroidism
Hypoparathyroidism is a common complication after bilat-
eral thyroid resections or total thyroidectomy. Up to 30%
of patients after total thyroidectomy develop temporary
hypoparathyroidism [29]. There are many identifiable risk
factors leading to postoperative hypoparathyroidism includ-
ing thyroidectomy for thyrotoxicosis and thyroid cancer,
thyroid reoperations, reduced stores of vitamin D, increased
extent of thyroid resection, and need of concomitant
central neck dissection [30, 31]. Patients undergoing thy-
roidectomy for thyroid cancer are particularly prone to
hypoparathyroidism because they often need a more com-
plete thyroid resection together with neck dissection. In fact,
total thyroidectomy and routine concomitant central neck
dissection has now been increasingly practiced worldwide
for almost types of well-differentiated thyroid cancer to
achieve lower recurrences, better disease-free survival, and
enhanced postoperative athyroglobulinemia [32]. However,
it has been shown that up to 60% of patients after
concomitant central neck dissection could develop transient
hypocalcemia secondary to the frequent occurrence of unin-
tentional or incidental parathyroidectomy [33]. Therefore,
in the presence of such a high incidence of postoperative
hypoparathyroidism, the need of routine postoperative inpa-
tient calcium monitoring remains questionable after thyroid
cancer surgery while the early routine administration of oral
calcium and/or vitamin D supplements seems to be relevant
and can facilitate the early discharge from hospital shortly
after surgery without developing unpleasant hypocalcemic
symptoms [34]. In fact, a recent randomized study supported
this strategy because routine administration of oral calcium
was shown to markedly reduce the severity and symptoms
of hypocalcemia [35]. However, the adoption of this strat-
egy could lead to overtreatment in patients who do not
have hypocalcaemia leading to rebound hypercalcemia and
increased medication costs. On the other hand, this strategy
might lead to inadequate treatment in patients with severe
symptomatic hypocalcaemia as oral calcium alone may not
fully correct the hypocalcemia and so vitamin D supplements
is indicated in such situation [36].
On the other hand, inpatient serial close monitoring of
serum calcium is recommended after total thyroidectomy
because most symptomatic hypocalcemia occurs around 24–
28 hours after surgery [37]. A 24-hour or longer hospital
stay is invariably required. Therefore, efforts are made to
shorten hospital stays, decrease biochemical blood tests,
and reduce hospital costs by adopting other strategies to
achieve early prediction of postthyroidectomy hypocalcemia.
With the availability of IOPTH and wide application in
patients undergoing minimally invasive parathyroidectomy
to predict postoperative cure, this new surgical adjunct has
been applied to thyroid surgery to monitor parathyroid
function and to predict the occurrence of postoperative
normocalcaemia or hypocalcaemia. In our early prospec-
tive study of using IOPTH in predicting hypocalcemia
in 100 consecutive patients (including 33 patients with
differentiated thyroid cancer) who underwent either total
or completion thyroidectomy, we found that a normal level
of IOPTH at 10mins or a level less than 75% decline in
IOPTH at 10mins after excision of thyroid gland accu-
rately identified normocalcemia [38]. It was suggested that
intraoperative or early postoperative parathyroid hormone
assay might be a sensitive tool to confirm postoperative
normocalcaemia and identify patients atrisk of developing
postoperative hypocalcaemia. Since then, up to 30 different
investigators have published their results of using various
different IOPTH assays in predicting hypocalcemia after
total thyroidectomy. The IOPTH levels and their rate of
decline at various time points after surgery could be utilized
for prediction of postoperative hypocalcaemia with variable
sensitivity, specificity, and accuracy [39, 40]. However, based
on two evidence-based reviews, it was recommended that
the IOPTH level within a few hours after thyroid surgery
could accurately predict postoperative normocalcaemia and
identify patients at-risk of developing hypocalcemia, par-
ticularly severe, symptomatic hypocalcemia [34, 41]. It
was suggested that patients could be stratified into high-
or low-risk groups and PTH should be measured at 1–
6 hrs after operation in comparison to preoperative PTH.
A < or > 65% decline at 6 hours after operation should
allow early discharge or facilitate the decision of early
calcium supplement. On the other hand, a strategy of 2
cut-off points should be considered with a high accuracy.
A <50% decline within few hours after surgery allowed
early discharge while a >90% decline necessitated early
calcium supplement because of the accuracy in predicting
normocalcaemia and hypocalcaemia, respectively [41]. For
those patients with 50%–90% decline, either serial calcium
monitoring or routine treatment should be considered. In
the AES guideline, one single serum PTH measurement is
recommended at 4 hrs after operation [42]. A normal PTH
can predict normocalcaemia, and patients can be discharged
early with 7% subsequently developing mild hypocalcaemia.
For patients with undetectable PTH level, oral calcium and
vitamin D analogue should be administered early to avoid
symptomatic hypocalcaemia. Intermediate or subnormal
PTH level is a less accurate predictor of hypocalcaemia. In
that case, oral calcium should commence or patients should
be monitored with serial calcium levels for the need of
calcium and/or vitamin D analogue [42]. Therefore, PTH
assay can now be considered as a perioperative adjunct to
predict normocalcaemia or hypocalcaemia with reasonable
accuracy. It can facilitate early discharge, avoid routine
calcium replacement, facilitate early calcium replacement to
avoid symptomatic hypocalcaemia and decrease overall cost
as well as increase patients’ satisfaction.
6. Conclusions
New technologies have undoubtedly had a positive impact on
the surgical management of thyroid cancer. The application
of endoscopic visualization of the thyroid gland has allowed
surgeons to perform safe surgery from extracervical skin
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incisions. Although short-term outcome studies in various
endoscopic techniques demonstrated comparative results as
conventional open thyroidectomy for differentiated thyroid
cancer, this particular operative approach is indicated for
selected patients only and the benefit is still considered
marginal with concerns of higher associated cost and longer
operating time in performing these procedures. Although the
robot procedures might offer some theoretical advantages
over the endoscopic procedures, better-designed prospective
comparative studies are required. Despite the lack of strong
evidence for the benefit of routine use of IONM, there
is a trend toward improved RLN protection and reduced
iatrogenic RLN injury. As a surgical adjunct, IOPTH is
being actively sought as a cost-effective tool for predicting
postoperative hypocalcaemia in patients undergoing total
thyroidectomy for thyroid cancer.
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